Resources Antibody Industry Trends Alzheimer’s Disease - Hope for the Future

Alzheimer’s Disease - Hope for the Future

Biointron 2023-11-30 Read time: 5 mins
Alzheimer’s Disease
Source: Getty Images

Research into treatments for Alzheimer's disease (AD) has reached impressive milestones this year. AD affects over 55 million individuals globally and while there is no cure, the first treatment to reduce disease progression rate was the antibody therapy Leqembi, which received full FDA approval in 2023.

AD is a progressive neurodegenerative disease marked by progressive dementia, starting with mild memory loss which can lead to loss of the ability to carry out simple, daily tasks. The main pathological features of AD involve the presence of abnormal amyloid protein plaques and tau tangles in the brain. 

The amyloid hypothesis suggests that the accumulation of amyloid beta (Aβ) deposits, resulting from excessive cleavage of amyloid precursor protein (APP), leads to synaptic and neuronal loss and ultimately causing brain atrophy. However, AD's exact origins remain unknown.

Alzheimer’s Disease
Source: Alzheimer’s Association

Traditionally, Alzheimer's treatments have focused on symptom management, with drugs like donepezil, rivastigmine, and galantamine seeking to improve cognitive function by enhancing brain acetylcholine levels. Memantine, an NMDA receptor antagonist, was introduced later to curb the harmful effects of excess glutamate. However, while these drugs offer symptomatic relief, they do not arrest or reverse disease progression. 

In a groundbreaking achievement this year, lecanemab became the first amyloid beta-directed antibody for AD approved by the FDA. Developed by Eisai and Biogen, Lecanemab is a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, thus reducing the formation of amyloid plaques in the brain. The Phase III Clarity-AD study demonstrated a 27% reduction in clinical decline compared to placebo after 18 months of treatment.

Lecanemab’s approval comes as a big win for the healthcare industry, as many antibody drugs with potential did not perform well in clinical studies. Just this week, a study was published on the phase II trial results for gosuranemab, a humanized IgG4 monoclonal antibody to N-terminal tau, for patients with early AD. Gosuranemab binds to tau monomers and fibrils to remove N-terminal tau from brain interstitial fluid, with the intention of reducing tau aggregation in cells. However, it did not meet its primary efficacy endpoint of change from baseline.

Alzheimer’s Disease
Source: Eisai

As of now, research efforts are ongoing for more potential antibody therapeutics to target AD. For instance, donanemab, an antibody developed by Eli Lilly, showed positive results, particularly in early symptomatic AD. Unlike lecanemab, donanemab binds to amyloid once the fibres have clumped together to become a larger build-up of plaque in the brain. 

Another recent paper describes a novel antibody 7C11, which was developed to bind to ApoE4, a key risk factor for sporadic AD. The APOE3 Christchurch (APOE3Ch) variant may provide resistance to AD from reduced pathological interactions between ApoE3Ch and heparan sulfate proteoglycans. As the 7C11 antibody was shown to reduce APOE-mediated toxicity and tau phosphorylation, its potential in clinical applications is highly valuable for patients.


Subscribe to our Antibody Industry Trends

Recent Antibody Industry Trends

The start of 2024 has seen leaps in deals for antibody therapeutics, especially ADCs (antibody-drug conjugates). This report aims to explore the events and trends of the biopharmaceutical industry in Q1. As of now, only two novel antibody drugs have been approved this year, but many more in regulatory review are expected to be fully approved.

Image credit: DOI: 10.1038/s41577-021-00542-xThe progress of COVID-19 therapies has seen remarkable strides, particularly in the development and application of antibody-based treatments. Early in the pandemic, the focus was on supportive care, but the rapid advancement in antibody therapies has sign

MAGMA-seq is an integrated technology for antibody wide mutational scanning. DOI:10.1038/s41467-024-48072-zThe use of bioinformatics and computational methods were of high interest in several papers published this past week. Protein language models, akin to natural language processing tools, p

DOI:10.1126/science.adg0564 B cells, or B lymphocytes, are a crucial component of the adaptive immune system andhumoral immunity. They originate from the bone marrow and mature in secondary lymphoid organs, such as the spleen and lymph nodes. The B ce

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.